OPK
OPKO Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.64
+1.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 587.9M | 606.9M | 713.1M | 863.5M | 1.0B |
| Cost of Revenue | 405.8M | 478.8M | 402.1M | 545.4M | 716.0M |
| Gross Profit | 182.1M | 128.1M | 311.0M | 318.1M | 288.2M |
| Operating Expenses | |||||
| R&D Expense | 125.2M | 124.0M | 105.2M | 89.6M | 73.9M |
| SG&A Expense | 205.8M | 223.0M | 304.2M | 300.6M | 372.7M |
| General & Admin Expense | 52.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 899.0K | — | 53.7M | 85.0M | 67.9M |
| Total Operating Expenses | 332.0M | 347.0M | 463.1M | 475.1M | 514.5M |
| Cost and Expenses | 737.7M | 825.9M | 865.2M | 1.0B | 1.2B |
| Operating Income (EBIT) | (149.8M) | (219.0M) | (152.1M) | (157.0M) | (226.3M) |
| Non-Operating | |||||
| Interest Income | 13.1M | 14.8M | 8.4M | 4.0M | 2.0M |
| Interest Expense | 45.0M | 108.5M | 47.5M | 13.5M | 12.1M |
| Net Interest Income | (31.9M) | (93.7M) | (39.0M) | (9.5M) | (10.1M) |
| Other Non-Op Income/Expense | 70.0M | (22.4M) | 141.7M | (27.4M) | (165.7M) |
| Non-Operating Income (excl Interest) | (110.0M) | (86.1M) | (189.2M) | 13.8M | 153.2M |
| EBT (Pre-Tax Income) | (79.8M) | (241.4M) | (10.4M) | (184.4M) | (391.9M) |
| Income Tax Expense | (7.0M) | (15.7M) | 42.8M | 4.4M | (63.5M) |
| Bottom Line | |||||
| Net Income | (72.9M) | (225.7M) | (53.2M) | (188.9M) | (328.4M) |
| Earnings from Cont. Ops | (72.9M) | (225.7M) | (53.2M) | (188.9M) | (328.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (72.9M) | (225.7M) | (53.2M) | (188.9M) | (328.4M) |
| Per Share | |||||
| Basic EPS | ($0.10) | ($0.30) | ($0.08) | ($0.25) | ($0.46) |
| Diluted EPS | ($0.10) | ($0.30) | ($0.08) | ($0.25) | ($0.46) |
| Revenue Per Share | $0.78 | $0.81 | $1.03 | $1.15 | $1.40 |
| Shares | |||||
| Basic Shares Outstanding | 755.3M | 751.1M | 694.0M | 751.8M | 719.1M |
| Diluted Shares Outstanding | 755.3M | 751.1M | 694.0M | 751.8M | 719.1M |
| Profitability Metrics | |||||
| EBITDA | 46.5M | (41.3M) | 135.3M | (65.5M) | (270.8M) |
| D&A | 86.3M | 91.6M | 98.2M | 105.3M | 108.7M |
| EBIT | (39.8M) | (132.9M) | 37.1M | (170.8M) | (379.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026